title: Microcapsules and transdermal patch: a comparative approach for improved delivery of antidiabetic drug.
abstract: Glibenclamide (GL)-loaded microcapsules (MC) and transdermal patches (TDP) were formulated and in vitro and in vivo parameters compared to find out the best route of drug administration. The formulation TDP1 having a drug-polymer ratio 1:1 showed comparatively higher GL release and better permeation across mice skin (p < 0.05). From the comparative study, it was concluded that the transdermal system of GL produced better improvement compared to oral microcapsule administration (p < 0.05). The transdermal system exhibited comparatively slow and continuous supply of GL at a desired rate to systemic circulation avoiding metabolism, which improved day-to-day glycemic control in diabetic subjects. Transdermal system of GL exhibited better control of hyperglycemia and prolonged plasma half-life by transdermal systems (9.6 +/- 1.2 h) in comparison with oral microcapsule (5.84 +/- 2.1 h), indicating that the drug, when administered by transdermal systems, will remain in the body for a longer period. From the glucose tolerance test, transdermal route effectively maintained the normoglycemic levels in contrast to the oral group (MC1), which produced remarkable hypoglycemia ranging from -12.6 +/- 2.1% to -18 +/- 2.3%. The significantly high (p < 0.05) area under the curve values observed with transdermal system (1,346.2 +/- 92.3 ng ml(-1) h(-1)) also indicate increased bioavailability of the drug from these systems compared to the oral route (829.8 +/- 76.4 ng ml(-1) h(-1)).
authors.affiliation: School of Pharmaceutical Sciences, SOA University, Bhubaneswar 751003, India. bmanojmishra@yahoo.com
authors.forename: Manoj K
authors.initials: MK
authors.lastname: Mishra
authors.forename: Debajyoti
authors.initials: D
authors.lastname: Ray
authors.forename: Bhakti B
authors.initials: BB
authors.lastname: Barik
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D005951:Glucose Tolerance Test; D005905:Glyburide / Q000008:administration & dosage / Q000493:pharmacokinetics; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D051379:Mice; D010316:Particle Size; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D014961:X-Ray Diffraction
chemical_list: D001786:Blood Glucose; D002214:Capsules; D007004:Hypoglycemic Agents; D005905:Glyburide